TARSUS PHARMACEUTICALS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $0 | $166.7M | $171.3M |
| FY2022 | $19.4M | $192.9M | $71.7M |
| FY2023 | $29.8M | $197.0M | $224.9M |
| FY2024 | $71.8M | $224.5M | $94.8M |
| FY2025 | $72.4M | $343.4M | $183.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $0 | $166.7M | $171.3M |
| FY2022 | $19.4M | $192.9M | $71.7M |
| FY2023 | $29.8M | $197.0M | $224.9M |
| FY2024 | $71.8M | $224.5M | $94.8M |
| FY2025 | $72.4M | $343.4M | $183.6M |